Introduction
============

Juvenile idiopathic arthritis (JIA) is a complex, autoimmune disease, characterized by persistent chronic arthritis. At present, the role of genetic and environmental factors in the development of the disease has been confirmed ([@b1-mmr-16-06-8793]). This disorder encompasses all forms of chronic arthritis and onset appears before 16 years of age, and usually persists for more than 6 weeks ([@b1-mmr-16-06-8793]). JIA is the most common rheumatic disease in children, with different disease manifestations in populations of different ethnicities or race. Currently, seven different subtypes of the disease have been distinguished according to the International League of Associations for Rheumatology (ILAR) classification ([@b2-mmr-16-06-8793]). However, the underlying mechanisms leading to a variety of different JIA phenotypes have not been delineated yet. Nowadays, numerous suggestions have been proposed to revise this classification ([@b3-mmr-16-06-8793]).

There is a strong genomic component to disease and a number of established susceptibility loci have been reported thus far ([@b4-mmr-16-06-8793]--[@b8-mmr-16-06-8793]). These data have been accumulated by using a variety of approaches, including candidate gene approaches and genome-wide association studies (GWAS). However, the pathophysiology and genetic etiology of the disease remains elusive. Most of the genetic predisposition to JIA was determined by the human leukocyte antigen (HLA) ([@b8-mmr-16-06-8793]--[@b10-mmr-16-06-8793]) and especially the HLA-DRB1 locus ([@b10-mmr-16-06-8793]), with its contribution to be estimated at a rate of approximately 20% ([@b11-mmr-16-06-8793]). Moreover, several non-HLA genes have been associated with JIA, including ATXN2, PTPN2, c12orf30, c3orf1, PTPN22, STAT4, TRAF1-C5, AFF3, CD247, CD226, MBL2, PSTPIP1, RANTES (CCL5), CTLA4, PRKCQ, PTPRC, TYK2, PRR9_LOR, ILDR1_CD86, WDFY4, PTH1R, RNF215, AHI1_LINC00271, JAK1, LINC00951, IL2RA, CCR5, COG6, ANGPT1, HBP1, 6q23/TNFAIP3, CXCR4 ([@b5-mmr-16-06-8793]--[@b7-mmr-16-06-8793],[@b12-mmr-16-06-8793]--[@b19-mmr-16-06-8793]). Of these loci, TRAF1, STAT4, TNFAIP3 and PRKCQ are good candidates considering the known pathogenesis of JIA as they are located within regions known to be involved in T-cell receptor signaling or activation pathways ([@b12-mmr-16-06-8793]). Furthermore, the role of family history regarding a higher prevalence of other autoimmune diseases among relatives of JIA patients has been confirmed ([@b11-mmr-16-06-8793]). No genetic risk factors common for sJIA and other JIA subtypes have been reported, thus suggesting that sJIA is a unique disease process ([@b20-mmr-16-06-8793]). A plethora of biomarkers has been suggested aiming to define the different JIA subtypes or predict either the course of the disease or treatment response (in specific therapies) ([@b21-mmr-16-06-8793]).

Not all independent replications in various cohorts have been successful, as shown by using the ImmunoChip single nucleotide polymorphism (SNP) array ([@b7-mmr-16-06-8793]) or by investigating an Australian cohort ([@b15-mmr-16-06-8793]). Different genetic variations have been reported as risk factors for JIA, but the difficulty to confirm previously collected results by analyzing populations of different ethnicities indicates the existence of a heterogeneity regarding the genetic factors that are involved in JIA.

Although numerous SNPs have been associated with JIA, only a few of these studies were replicated and validated. In the present study, we aimed to validate three SNPs, namely PTPRC (rs10919563), TYK2 (rs34536443) and PRKCQ (rs4750316), previously found to be associated with JIA ([@b7-mmr-16-06-8793],[@b12-mmr-16-06-8793],[@b22-mmr-16-06-8793]) and to investigate whether the 27-bp VNTR polymorphism on intron 4 of endothelial nitric oxide synthase (eNOS), which is associated with various autoimmune diseases, is associated with risk for JIA in Greece.

Patients and methods
====================

### Patient population and study design

The sample set consisted of 125 JIA patients followed in two departments (the Rheumatology Unit of the 4th Medical Department of Internal Medicine and the Rheumatology Unit of the 1st Medical Department of Pediatrics) of the Aristotelian University of Thessaloniki Hospital (Thessaloniki, Greece). In this study, only patients who fulfilled the 2001 revised ILAR criteria for JIA were enrolled. Written informed consent was obtained from parents for those patients who were \<18 years of age. A total of 221 unrelated healthy individuals, sex- and ethnic-matched selected from the Transfusion Medicine Department of Hippokration Hospital of Thessaloniki, served as controls for the genotyping ([@b14-mmr-16-06-8793]). The study was approved by the local Ethics Committee for medical research and was carried out in compliance with the Declaration of Helsinki.

### Genotyping

A panel of 3 SNPs was genotyped in a Greek cohort of JIA patients and healthy controls, including *PTPRC* rs10919563, *PRKCQ* rs4750316 and *TYK2* rs34536443. Moreover, the 27-bp VNTR polymorphism on intron-4 of *eNOS* was analyzed, considering its previous association with multiple complex diseases ([@b23-mmr-16-06-8793]). Genomic DNA was isolated from peripheral blood leukocytes by using the commercial kit Puregene (Gentra Systems, Minneapolis, MN, USA) according to the manufacturer\'s instructions.

Allelic discrimination of PTPRC rs10919563, PRKCQ rs4750316 and TYK2 rs34536443 SNPs was carried out using premade TaqMan SNP Genotyping assays from Applied Biosystems (Foster City, CA, USA), according to the Applied Biosystems protocol (cat. nos. C_31565763_10, C_32036787_10 and C\_\_60866522_10 for rs10919563, rs4750316 and rs34536443, respectively). A 96-well plate was prepared with a mixture on an Applied Biosystems ViiA™ 7 Real-Time PCR system of 1X TaqMan SNP Genotyping assay, 1X TaqMan Universal Master mix (both from Applied Biosystems) and 20 ng DNA per well. After PCR, the plates were read, and the data analyzed using Quant Studio™ Real-Time PCR software (Applied Biosystems). Each assay was run with negative controls. For quality control, a random 10% of the samples were amplified twice to ensure accuracy of the results, with a reproducibility rate of 100%. Genotyping of eNOS gene intron 4 a/b VNTR polymorphism was performed as described in detail elsewhere ([@b23-mmr-16-06-8793]). Upon PCR amplification, the 420-bp band indicated five repeats of the 27-bp sequence and the 393-bp band represented four repeats, corresponding to b and a alleles, respectively ([@b24-mmr-16-06-8793]).

### Construction of a three-dimensional (3D) model

A bioinformatics analysis was performed using BlastP (for sequence analysis) on the Uniprot sequence database. PyMOL (DeLano Scientific, San Carlos, CA, USA) was used for the direction of the development of a 3D model. Maestro and Desmond (Schrödinger, Inc., New York, NY, USA) were used aiming to analyze mutations and stability of the protein model. The initial 3D model used was based on the crystal structure of *Homo sapiens* TYK2.

### Statistical analysis

The GraphPad Prism statistical program (GraphPad Software, San Diego, CA, USA) was used in the framework of the analyses conducted. A two-tailed P\<0.05 was defined as statistically significant. Odds ratios (OR) and 95% confidence intervals (CI) were calculated. The possible deviation from Hardy-Weinberg equilibrium (HWE) was performed by using the program 'Calculate' (Copyright TRG, SR, INMD, 2008).

Results
=======

### Developing a 3D model of TYK2 protein

Aiming to gain insight to the potential structural/functional consequences of rs34536443 SNP, which has been associated with various rheumatic and other complex human diseases, we further analyzed the respective region of TYK2 protein by developing a new 3D model, improving the pre-existing one developed by Myrthianou *et al* ([@b26-mmr-16-06-8793]). The rs34536443 SNP leads to the substitution of a G to a C nucleotide, thus resulting in a Pro1104Ala mutation in the TYK2 protein. Accordingly, replacement of the Pro1104 amino acid residue of the protein TYK2 may introduce a conformational change that may extend the α-helical segment by five more residues ([Fig. 1](#f1-mmr-16-06-8793){ref-type="fig"}). Thus, it is possible that the local 3D structure may be altered and, consequently, the folding of TYK2 protein may be affected. These alterations are supposed to affect the protein from the functionality viewpoint. Subsequent analyses of molecular dynamics of the mutant TYK2 demonstrated further folding changes at the level of the structure of the protein ([Fig. 1](#f1-mmr-16-06-8793){ref-type="fig"}).

### Investigating a potential genetic association of TYK2, PTPRC and eNOS SNPs with JIA

In the context of this case-control study, three successful markers were analyzed. The allelic and genotype frequencies of the *eNOS* VNTR of patients and controls are shown in [Table I](#tI-mmr-16-06-8793){ref-type="table"}. The homozygous genotype b/b appeared the higher frequency in controls as well as JIA patients (73.30 vs. 48%, respectively). Importantly, a/a genotypes had a frequency that was associated with disease occurrence (p\<0.0001, OR=0.15, 95% CI: 0.065--0.37). Moreover, the frequency of the *eNOS* intron-4 'a' allele of JIA patients was associated with the disease, being higher in comparison to that of the controls (33.2 vs. 14.71%; p\<0.0001, OR=0.34, 95% CI: 0.23--0.49). These data indicated the 27-bp *eNOS* VNTR with JIA in Greece.

Notably, the remaining two SNPs PTPRC (rs10919563) and TYK2 (rs34536443) were found to be associated with JIA apart from previous findings that suggested a genetic association between these SNPs and JIA in different ethnic populations ([@b6-mmr-16-06-8793],[@b22-mmr-16-06-8793]). Thus, patients with JIA did not present higher frequencies either for the GG genotype or G allele of the PTPRC rs10919563 SNP (p=0.41, OR=0.3, 95% CI: 0.03--2.6; and p=0.49, OR=0.82, 95% CI: 0.52--1.31, respectively) (data not shown). Moreover, concerning the TYK2 rs34536443 SNP, no statistical significant differences were observed between patients and controls either at genotype or allelic level (p=0.34, OR=2.50, 95% CI: 1.53--11.75; and p=0.34, OR=2.45, 95% CI: 0.53--11.55 for G/C genotype and minor allele C, respectively) (data not shown). All the gene polymorphisms examined were found to be under HWE (P\>0.01).

In our attempt to analyze a possible association of the polyarticular and oligoarticular course of JIA with the two SNPs and the 27-bp VNTR under study, a further genetic analysis was conducted but no association was observed. Considering the moderate size of our sample, which precluded any detailed subtype-specific association analyses, it is understood that such a subtype analysis must be conducted in a larger cohort, consisted of adequately sized samples, in order to lead to a high statistical power.

Search for a sex-specific genetic association of PRKCQ rs4750316 SNP with JIA. A genetic association study was performed involving the *PRKCQ* rs4750316 SNP ([Table II](#tII-mmr-16-06-8793){ref-type="table"}). However, no significant association of the minor allele C of rs4750316 with JIA was observed (p=0.62, OR=1.12, 95% CI: 0.75--1.68). Nevertheless, preliminary unpublished data collected from different ethnic populations have previously shown *PRKCQ* rs4750316 SNP to be associated with JIA specifically to males. Therefore, a sex-stratified analysis was conducted in the Greek samples but no sex-based difference in the frequency of this allele was observed between patients (p=0.14, OR=1.80, 95% CI: 0.88--3.64 vs. p=0.16, OR=0.61, 95% CI: 0.32--1.17, respectively). Given that the sex bias differs in the JIA subtype, these associations should be further investigated in individual subtypes. However, the small sample size did not allow for further analyses, depending on JIA subtype at level of a statistical certainty, to be performed.

Discussion
==========

Accumulated evidence has indicated the existence of a heterogeneity, depending on the population\'s ethnicity, of genetic factors involved in the development of autoimmune diseases. Deepening of our knowledge regarding the homogeneity or heterogeneity at the level of alleles that is associated with these diseases may confer to a more reasonable understanding of plausible common gene function and pathways. To the best of our knowledge, the present analysis revealed for the first time that eNOS VNTR polymorphism is associated with susceptibility to JIA and, therefore, suggests a role for the risk allele 'a' in the development of different autoimmune diseases. In a previous study, referring to a Greek population, the implication of eNOS gene 27-bp VNTR in susceptibility to rheumatoid arthritis (RA) was identified ([@b23-mmr-16-06-8793]). Moreover, in that study, the implication of this VNTR to systemic lupus erythematosus (SLE) was shown ([@b23-mmr-16-06-8793]). In the present study, it was found that the presence of a/b genotype or 'a' allele may be a disease-susceptibility factor for RA or lupus glomerulonephritis.

The functional role of nitric oxide (NO) regarding the cell pathophysiology and function has been previously analyzed. Thus, it has been suggested that it is a potent mediator in different biological reactions, which is involved in various responses based either on inflammation or autoimmunity processes. NO was suggested to be an inhibiting factor for proinflammatory gene expression in endothelial cells or an activator of resident leukocytes ([@b27-mmr-16-06-8793]). Obviously, gene polymorphisms or other factors that influence the expression of the enzyme eNOS that catalyzes the synthesis of NO can be considered as key genes for the control of NO levels activity. For the maintenance of physiological endothelial function, low levels of NO are needed ([@b28-mmr-16-06-8793]). Although the functional significance of eNOS gene VNTR on protein activity and expression is not well documented yet, some preliminary experiments have managed to clarify this issue. The a allele has been related to low NO metabolite levels, and a/a homozygotes were found to produce lower NO metabolite levels compared to b/b individuals ([@b29-mmr-16-06-8793]). In addition, it has been shown that the 27-bp VNTR of eNOS is able to bind nuclear proteins acting either as an enhancer or repressor, thus promoting or suppressing transcription efficiency ([@b30-mmr-16-06-8793]). Therefore, apart from the suggested crucial role of the eNOS VNTR under discussion dealing with the decreased gene expression of eNOS in allele 'a' carriers, the possibility of its proximity and, therefore, of a linkage disequilibrium with other variants cannot be underestimated.

An association of eNOS gene with various multifactorial diseases, including as primary biliary cirrhosis ([@b31-mmr-16-06-8793]), RA ([@b23-mmr-16-06-8793]), type-1 and −2 diabetes ([@b32-mmr-16-06-8793]) and SLE ([@b23-mmr-16-06-8793],[@b33-mmr-16-06-8793]) has been shown thus far. However, a dependence of JIA and eNOS polymorphisms according to race or ethnicity has been suggested. Indeed, an association of the eNOS VNTR polymorphism with SLE was shown in the past in Turkey ([@b33-mmr-16-06-8793]) but not in Greece ([@b23-mmr-16-06-8793]) or with RA in Greece ([@b23-mmr-16-06-8793]) but not in Serbia ([@b34-mmr-16-06-8793]).

Notably, although it was previously shown that PTPRC rs10919563 ([@b6-mmr-16-06-8793]), PRKCQ rs4750316 ([@b12-mmr-16-06-8793]) and TYK2 rs34536443 ([@b22-mmr-16-06-8793]) SNPs play a role in the phenotypical manifestations accompanying JIA, the present study did not confirm association of the SNPs examined with the disease in Greece.

It is well known that the high female:male sex-ratio is a characteristic observed in almost all autoimmune diseases, including JIA. Recently, a sex-specific pattern of association with JIA has been reported. Particularly, a female-association of PTPN22 rs2476601 was detected with JIA in different ethnic populations, including the Greek one ([@b35-mmr-16-06-8793]). In this framework, the rs4750316 SNP of PRKCQ was analyzed as well, taking into account that it was demonstrated originally to exhibit an association with JIA in a first analysis conducted in 2010 ([@b12-mmr-16-06-8793]), thus appearing as a promising JIA candidate gene in the UK cohort. However, this finding was not confirmed in the same population when an analysis by ImmunoChip array was performed ([@b7-mmr-16-06-8793]). Notably, an association of this SNP with JIA was found recently in samples from different ethnicities, stratified by sex (unpublished data). While in the Greek population an analysis for rs4750316 SNP did not reach statistical significance, more solid data are to be obtained by increasing the sample size and further investigating any new data.

It is worth mentioning that a study performed by using the Immunochip and next generation sequencing approaches has shown that allele 'C' of rs34536443 of TYK2 was protective for inflammatory bowel disease, RA and SLE ([@b36-mmr-16-06-8793]) but conferred a risk for psoriasis ([@b37-mmr-16-06-8793]) and JIA ([@b6-mmr-16-06-8793]). In the framework of an analysis conducted in a UK cohort by ImmunoChip array ([@b7-mmr-16-06-8793]), TYK2 rs34536443 was not found to be associated with JIA, a result that coincides with the present data from the Greek cohort. This finding was noteworthy considering that TYK2 rs34536443 SNP was found recently, in a study performed in the Greek population ([@b26-mmr-16-06-8793]), to exhibit a genetic overlap with PsA and RA that is well known to possess or share several similar clinical manifestations with JIA. Moreover, according to the constructed 3D model of TYK2 protein and previous observations of our group ([@b26-mmr-16-06-8793]), it is assumed that the Pro1104Gly mutation may affect the protein\'s functionality by affecting elements contributing to the structural conformation of the molecule.

According to the data of the present study, minor allele frequencies (MAFs) of PRKCQ (rs4750316), TYK2 (rs34536443) SNPs and eNOS VNTR were lower in healthy individuals from Greece in comparison to samples analyzed by other investigators working with different ethnic/racial populations ([@b6-mmr-16-06-8793],[@b14-mmr-16-06-8793],[@b22-mmr-16-06-8793],[@b37-mmr-16-06-8793],[@b38-mmr-16-06-8793]). This finding suggests that existing population-specific differences influence the frequency of these alleles. Thus, there is still the possibility that an association of TYK2 rs34536443 with JIA may be detected if the cohort size is increased. However, given the MAF of the minor allele C of this SNP in the controls from Greece (0.22), it can be assumed that a high number of patients and controls was required to be collected (probably higher than 5,000 for each category) to obtain an 80% power of the study (at p=0.05) ([@b26-mmr-16-06-8793]).

Findings of this study highlight the importance of conducting comparative studies in different populations, considering that replication of previously identified markers is paramount to determine which SNPs are true risk loci, thus suggesting key disease pathways which require further study. Additionally, the ultimate task upon a proper functional validation of these SNPs is the translation of any findings into a better management of specific groups of patients with JIA.
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###### 

Genotype and allele frequencies of the 27-bp eNOS VNTR analyzed in 125 JIA patients and 221 healthy controls.

  Variables   JIA (N=125)   Controls (N=221)   P-value        OR (95% CI)
  ----------- ------------- ------------------ -------------- --------------------
  Genotypes                                                   
    b/b       60 (48%)      162 (73.30%)                      
    b/a       47 (37.6%)    49 (22.17%)        0.05           0.4 (0.16--1.02)
    a/a       19 (15.2%)    8 (3.63%)          **\<0.0001**   0.15 (0.065--0.37)
  Alleles                                                     
    B         167 (66.8%)   373 (84.39%)                      
    A         85 (33.2%)    65 (14.71%)        **\<0.0001**   0.34 (0.23--0.49)

eNOS, endothelial nitric oxide synthase; JIA, juvenile idiopathic arthritis; OR, odds ratio; CI, confidence interval. Bold, statistically significant.

###### 

Frequencies of the minor allele 'C' of PRKCQ rs4750316 SNP in a sex-stratified genetic analysis.

  Gene    SNP         Samples   N cases/N controls   OR (95% CI)         P-value
  ------- ----------- --------- -------------------- ------------------- ---------
  PRKCQ   rs4750316   All       144/185              1.12 (0.75--1.68)   0.62
                      Males     36/129               1.80 (0.88--3.64)   0.14
                      Females   108/56               0.61 (0.32--1.17)   0.16
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